ClinicalTrials.gg
CompletedNCT05392998Updated Mar 18, 2024Results posted

Tolerance to Residual Astigmatism in Eyes With Vivity®

An observational study in Lenses, Intraocular, sponsored by Clínica Rementería. Completed at 1 site in Spain. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Clínica Rementería · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Astigmatism with a site in Spain — 2 open to participants now, 2 under way, none of them phase 3. Astigmatism · Spain.

Started
2021
with 4 others
Observational
4 of 16
none open now
Registered
11th of 16
by date
Lead sponsor
1 of 16
Clínica Rementería

Among the 16 studies in Astigmatism with a site in Spain, this one is one of 5 that started in 2021, is one of 4 observational ones, and was the 11th registered.

Astigmatism

418 studies on the registry are indexed under Astigmatism; 51 are open to participants now.

Browse Astigmatism studies →

Open to participants now

2 of the 16 studies in Astigmatism with a site in Spain are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Astigmatism with a site in Spain, or all of them as a file.
02

Study summary

Low amounts of postoperative residual astigmatism may worsen the visual performance of patients implanted with presbyopia- correcting intraocular lenses (IOLs). Although extended depth of focus (EDoF) IOLS have introduced optical improvements, it is important to determine the tolerance of these IOLs to postoperative astigmatism. This is important for an appropriate surgical planning.

Therefore, the aim of this study is to simulate and assess the impact of mild amounts of residual mixed astigmatisms with the axis oriented in different positions (vertical, oblique and horizontal) in eyes implanted with the Vivity® IOL.

Read the detailed description

Objectives:

  • Primary objective: To describe the tolerance of simulated astigmatism on patients implanted with Vivity at far distance.
  • Secondary objective: To describe the tolerance of simulated astigmatism on patients implanted with Vivity at intermediate distance.

Study Design: Prospective, single arm, descriptive, 3-month follow up.

Patient population: 30 consecutive eyes of 30 patients implanted with Vivity bilaterally with no postoperative complications. The calculation of the required sample size was based on monocular corrected distande visual acuity. A difference of 0.2 logMAR units was assumed to be clinically significant anda standard deviation of 0.05 was anticipated(data obtained from a comparative study between a bifocal and a trifocal IOL: Jonker SM, et al. Journal of Cataract Refract Surg. 2015; 41: 1631-40). Based on these assumptions, with an α of 0.05 and power of 0.8, it was calculated that 25 eyes were required in each group. Due to potential dropouts, a larger sample size has been selected.

Clinical Protocol: All patients fullfilling study criteria will be considered for inclusion three months after surgery. After patient consent, uncorrected distance visual acuity will be measured with an ETDRS chart, followed by subjective refraction (best distance correction). In all cases, mixed astigmatism will be induced with trial lens over the best distance corrected situation (considered the reference situation).

Once the best distance correction is determined, the different visual acuity evaluation procedures for this study will be performed with a Freiburg Acuity Test software package. The software will be run on a separate laptop screen calibrated to be presented at 4 meters. In this procedure, a black Landolt C is presented to the subjects and, among 8 different possibilities, they indicate the orientation of the optotype on a numeric keypad. This test minimizes the observer's bias because the presented optotype depends on the patient´s previous responses. That is, when the observer responds to a certain optotype, the software automatically modifies the size of the next optotype according to parameter estimation by a sequential test method. (7,8) Finally, all serious adverse events will be reported.

Statistical Analysis: Visual acuity values will be expressed as mean and standard deviation. Normal distribution of variables will be assessed using the Kolmogorov- Smirnov test. Pre- and post-operative data of each parameter will be compared by means of the Student's t-test. A repeated measure analysis of variance (ANOVA) will be used to gauge any statistically significant difference of the data within the different simulated situations. Differences are considered to be statistically significant for P value \<0.05 (i.e., at the 5% level).

03

Conditions studied

  • Lenses, Intraocular

Browse trials for

Keywords

  • extended depth of focus intraocular lens
  • astigmatism
04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing bilateral cataract surgery with bilateral Vivity intraocular lens implantation, with no other ocular diseases and no complications

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients >40 years old that undergo routine cataract surgery
  • Bilateral implantation of Vivity ® IOL

Exclusion criteria

Exclusion Criteria:

  • Corneal astigmatism ≥1.0 diopters (D )
  • Amblyopia
  • Previous ocular surgery
  • Presence of ocular pathologies
  • Abnormal iris
  • Patients with intra- or postoperative complications
  • Postoperative best distance corrected visual acuity (BDCVA) \< 20/20
  • Postoperative refractive astigmatism > 0.50D
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Vivity patients

    The study will include patients \>40 years old that undergo routine cataract surgery and implantation of Vivity ®. Exclusion criteria include corneal astigmatism ≥1.0 diopters (D ), amblyopia, previous ocular surgery and presence of ocular pathologies and abnormal iris. Patients with intra- or postoperative complications, with a postoperative best distance corrected visual acuity (BDCVA) \< 20/20 and with postoperative refractive astigmatism \> 0.50D will be also excluded . Inclusion and exclusion criteria will be assessed by an ophthalmologic examination including refraction, screening for ocular conditions and/or systemic diseases, slit-lamp biomicroscopy and fundus examination.

    Device: Cataract surgery with Vivity intraocular lens implantation

Interventions

  • DeviceCataract surgery with Vivity intraocular lens implantation

    Cataract surgery with Vivity intraocular lens implantation

06

What researchers measure

Primary outcomes

  1. Distance Against the Rule Astimatism

    Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x0\*, taking as a reference the subjects' axis

    Time frame: Three months after surgery

  2. Distance Oblique Astigmatism

    Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x45\*, taking as a reference the subjects' axis

    Time frame: Three months after surgery

  3. Distance With the Rule Astigmatism

    Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x90\*, taking as a reference the subjects' axis

    Time frame: Three months after surgery

07

Results

Posted Mar 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneVivity Patients
Started30
Completed30
Not completed0

Outcome measures

PrimaryDistance Against the Rule Astimatism

Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x0\*, taking as a reference the subjects' axis

Time frame:
Three months after surgery
Reported as:
Mean · LogMAR
Distance Against the Rule Astimatism
LogMARVivity Patients
Distance Against the Rule Astimatism0.01 ± 0.04
PrimaryDistance Oblique Astigmatism

Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x45\*, taking as a reference the subjects' axis

Time frame:
Three months after surgery
Reported as:
Mean · LogMAR
Distance Oblique Astigmatism
LogMARVivity Patients
Distance Oblique Astigmatism0.01 ± 0.06
PrimaryDistance With the Rule Astigmatism

Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x90\*, taking as a reference the subjects' axis

Time frame:
Three months after surgery
Reported as:
Mean · LogMAR
Distance With the Rule Astigmatism
LogMARVivity Patients
Distance With the Rule Astigmatism0.01 ± 0.05

Adverse events

Collected over Three months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vivity Patients0/30 (0%)0/30 (0%)0/30 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vivity Patients
Mean69.37 ± 7.10
Sex: Female, Male
Sex: Female, Male(Participants)Vivity Patients
Female19
Male11
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Vivity Patients
08

Study locations

1 site
  • Clínica Rementería
    Madrid, 28010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Data will be shared after reasonable request

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Mar 2022, 8 months.

Results were first posted in Mar 2024, 2 years after primary completion.

Of 35 observational studies under Astigmatism, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 92. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
May 26, 2022
StartActual
Jun 16, 2021
Primary completionActual
Mar 9, 2022
CompletionActual
Mar 9, 2022
Results first posted
Mar 18, 2024
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05392998
Lead sponsor
Clínica Rementería
Collaborators
Alcon Research
Responsible party
Sponsor
First posted
May 26, 2022
Start date
Jun 16, 2021
Primary completion
Mar 9, 2022
Completion
Mar 9, 2022
Results posted
Mar 18, 2024
Last update
Mar 18, 2024

Study contacts

Laureano Rementeria-Capelo, MD
principal investigator · Clínica Rementería

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion